Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N.

Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10.

PMID:
30531871
2.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.

3.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ.

Clin Cancer Res. 2016 Nov 15;22(22):5514-5526. doi: 10.1158/1078-0432.CCR-15-1984. Epub 2016 Jun 1.

4.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.

Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.

5.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

6.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

7.

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.

Giessrigl B, Schmidt WM, Kalipciyan M, Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader RM, Krupitza G.

Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.

8.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.

9.

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.

10.

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.

Knudsen ES, Witkiewicz AK.

Oncotarget. 2016 Oct 25;7(43):69111-69123. doi: 10.18632/oncotarget.11588.

11.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

12.

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.

13.

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.

Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.

Int J Oncol. 2007 Feb;30(2):509-20.

PMID:
17203234
14.

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.

Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.

Cell Physiol Biochem. 2018;51(4):1518-1532. doi: 10.1159/000495643. Epub 2018 Nov 29.

15.

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY.

PLoS One. 2014 Sep 9;9(9):e107369. doi: 10.1371/journal.pone.0107369. eCollection 2014.

16.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

17.

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.

Chen Z, Wang Y, Warden C, Chen S.

J Steroid Biochem Mol Biol. 2015 May;149:118-27. doi: 10.1016/j.jsbmb.2015.02.004. Epub 2015 Feb 12.

18.

Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.

Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ, Chen S.

Breast Cancer Res Treat. 2015 Jul;152(1):29-39. doi: 10.1007/s10549-015-3446-8. Epub 2015 May 31.

19.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.

Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707.

20.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

Supplemental Content

Support Center